Valuation : Silence Therapeutics plc

Market Cap 658M 890M 766M 719M 1.23B 84.18B 1.24B 8.51B 3.31B 43.02B 3.34B 3.27B 139B P/E 2026 *
-21.9x
P/E 2027 * -18.1x
Enterprise Value 525M 710M 611M 574M 979M 67.15B 987M 6.78B 2.64B 34.32B 2.67B 2.61B 111B EV / Sales 2026 *
1,616x
EV / Sales 2027 * 645x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Silence Therapeutics plc

1 week+9.96%
Current month+9.31%
1 month+38.48%
3 months+130.73%
6 months+161.08%
Current year+143.26%
1 week 13.09
Extreme 13.0896
15.28
1 month 10.86
Extreme 10.86
17.58
Current year 4.19
Extreme 4.19
17.58
1 year 4.19
Extreme 4.19
17.58
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 01/12/2025
Director of Finance/CFO 54 01/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/01/2004
Director/Board Member 65 05/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Sell 865,112 0.6105%
02/01/26 Free

Chief Financial Officer

375,000 0.2646%
02/01/26 Free

Director

90,000 0.0635%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+9.96%+195.21%+74.00% 890M
-0.24%-1.09%+2.00%+18.17% 50.35B
+0.78%-4.65%+430.22%+501.63% 45.2B
+2.95%+3.52%+47.12%+21.08% 44.71B
+0.25%-2.63%+7.86%+73.60% 41.24B
+0.43%-2.20%+14.55%+49.08% 33.08B
+1.43%+8.73% - - 17.81B
+0.06%-2.97%+23.31%+116.96% 16.56B
+0.93%+0.63%+16.86%+29.70% 14.82B
+0.54%-1.03%+80.71%+39.94% 14B
Average +0.71%+0.86%+90.87%+102.68% 27.86B
Weighted average by Cap. +0.82%-0.61%+93.53%+123.41%

Financials

2026 *2027 *
Net sales 325K 440K 378K 355K 606K 41.56M 611K 4.2M 1.64M 21.24M 1.65M 1.61M 68.39M 751K 1.02M 874K 820K 1.4M 96.04M 1.41M 9.7M 3.78M 49.08M 3.82M 3.73M 158M
Net income -41.45M -56.11M -48.28M -45.3M -77.36M -5.3B -77.98M -536M -209M -2.71B -211M -206M -8.73B -66.28M -89.73M -77.2M -72.45M -124M -8.48B -125M -857M -334M -4.33B -337M -330M -13.96B
Net Debt -133M -180M -155M -145M -248M -17.03B -250M -1.72B -670M -8.7B -677M -662M -28.03B -174M -236M -203M -190M -325M -22.27B -327M -2.25B -876M -11.38B -885M -865M -36.66B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
03/09/26 $14.79 0.00% 572,406
02/09/26 $14.79 +0.34% 634,202
01/09/26 $14.74 +8.94% 1,134,889
31/08/26 $13.53 +0.82% 478,194
28/08/26 $13.42 -0.22% 539,704
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.79USD
Average target price
33.00USD
Spread / Average Target
+123.12%

Quarterly revenue - Rate of surprise